CMV viral load in bronchoalveolar lavage for diagnosis of pneumonia in allogeneic hematopoietic stem cell transplantation
| Autor: | L Torres-Miñana, M M Perera, M J Pena-López, L Iglesias |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Adolescent medicine.medical_treatment 030106 microbiology Pneumonia Viral Cytomegalovirus Hematopoietic stem cell transplantation medicine.disease_cause Gastroenterology Bronchoalveolar Lavage Article 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine Humans 030212 general & internal medicine Aged Transplantation medicine.diagnostic_test business.industry Incidence (epidemiology) Hematopoietic Stem Cell Transplantation Hematology Middle Aged medicine.disease Allografts respiratory tract diseases Pneumonia Graft-versus-host disease Bronchoalveolar lavage Immunology Cytomegalovirus Infections Infectious diseases Female business Viral load Haematological diseases Follow-Up Studies |
| Zdroj: | Bone Marrow Transplantation |
| ISSN: | 1476-5365 |
| Popis: | The objective of this report is to analyze the value of CMV viral load (VL) in bronchoalveolar lavage (BAL) in recipients of allogeneic hematopoietic stem cell transplantation (AHSCT) and to analyze the concordance between CMV quantification in plasma and BAL samples. Fifty-six patients were included; in 16 (28.6%) patients with symptoms of lung disease a BAL sample was collected, 7 (43.7%) patients had a VL >150 copies/mL (six had probable CMV pneumonia). Patients with CMV pneumonia were female (100%), of median age 53.5 years, and the median time from transplantion to onset of symptoms was 67.5 days. Pneumonia was early in three cases (incidence 5.4%). Median BAL VL was 53 250 copies/mL and plasma VL was 538 copies/mL (in one patient, the plasma VL was negative). Three (50.0%) patients had an improvement in the first week of treatment, and plasma VL became negative; the other 3 (50.0%) patients died with a CMV pneumonia refractory to treatment. Therefore, any value of CMV VL in BAL, especially if it is greater than plasma, with compatible signs or symptoms, should be considered suggestive of CMV pneumonia in recipients of AHSCT and they should receive specific treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink